Top of this page
Skip navigation, go straight to the content

Newsroom January 2016


In Europe, Briviact® (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.


January, 2016

Briviact EU

In Focus archive